Morgan Stanley’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $39M | Buy |
16,865,082
+18,708
| +0.1% | +$43.2K | ﹤0.01% | 2150 |
|
|
2025
Q1 | $23.4M | Sell |
16,846,374
-793,992
| -5% | -$1.1M | ﹤0.01% | 2536 |
|
|
2024
Q4 | $30.5M | Buy |
17,640,366
+9,976,373
| +130% | +$17.3M | ﹤0.01% | 2322 |
|
|
2024
Q3 | $15.4M | Buy |
7,663,993
+186,596
| +2% | +$375K | ﹤0.01% | 3057 |
|
|
2024
Q2 | $16.7M | Buy |
7,477,397
+2,308,507
| +45% | +$5.17M | ﹤0.01% | 2858 |
|
|
2024
Q1 | $14.8M | Buy |
5,168,890
+4,735,814
| +1,094% | +$13.6M | ﹤0.01% | 3000 |
|
|
2023
Q4 | $767K | Buy |
433,076
+261,007
| +152% | +$462K | ﹤0.01% | 5429 |
|
|
2023
Q3 | $544K | Buy |
172,069
+40,761
| +31% | +$129K | ﹤0.01% | 5131 |
|
|
2023
Q2 | $86.8K | Buy |
131,308
+43,495
| +50% | +$28.8K | ﹤0.01% | 6010 |
|
|
2023
Q1 | $70K | Buy |
87,813
+64,206
| +272% | +$51.2K | ﹤0.01% | 6145 |
|
|
2022
Q4 | $53.4K | Sell |
23,607
-1,355
| -5% | -$3.06K | ﹤0.01% | 6262 |
|
|
2022
Q3 | $48K | Sell |
24,962
-46,689
| -65% | -$89.8K | ﹤0.01% | 6430 |
|
|
2022
Q2 | $265K | Sell |
71,651
-104,104
| -59% | -$385K | ﹤0.01% | 5752 |
|
|
2022
Q1 | $1.15M | Buy |
175,755
+33,410
| +23% | +$218K | ﹤0.01% | 4897 |
|
|
2021
Q4 | $1.66M | Buy |
142,345
+17,251
| +14% | +$201K | ﹤0.01% | 4718 |
|
|
2021
Q3 | $2.33M | Buy |
125,094
+88,984
| +246% | +$1.66M | ﹤0.01% | 4449 |
|
|
2021
Q2 | $766K | Buy |
36,110
+13,149
| +57% | +$279K | ﹤0.01% | 5240 |
|
|
2021
Q1 | $466K | Sell |
22,961
-8,377
| -27% | -$170K | ﹤0.01% | 5191 |
|
|
2020
Q4 | $832K | Buy |
+31,338
| New | +$832K | ﹤0.01% | 4769 |
|